VANCOUVER, BC – TheNewswire - June 16, 2021 - AREV NANOTEC BRANDS INC. (CSE:AREV) (OTC:AREVF) (CNSX:AREV.CN) (“AREV” or the “Company”) Through its subsidiary AREV Cambodia is pleased to announce the Company has completed its land survey and soil analysis for cultivation of mushrooms, moringa and breadfruit.

Mr. Rem Sareub, Head of Agriculture for AREV Cambodia has completed the soil and land survey of the company’s 20 hectare leased land parcel in the Stoung District of Cambodia. The land has sufficient water resources for rainy and dry seasons. The land is surrounded by an irrigation canal with ground water at a depth of 1.5 meters and is a plateau that will not flood. The soil is grey sandy clay with worms and beneficial insects and has a pH of 7. The NPK is ideal and not salty with fair alkalinity levels.  The analysis definitively indicates that the land is excellent for the organic cultivation of the several strains of functional mushrooms, Moringa and breadfruit that can be used in the Company’s Ready-to-Use Therapeutic Food (RUTF) product into our SUS-TAINN™ product in development.

Mushrooms are a very good source of protein for meat substitutes and are natural medicine factories. The following are the type of mushrooms grown by Mr. Rem, an expert in the agriculture field. Mr. Rem has successfully cultivated a variety of mushrooms, including Birch Polypore (Fomitopsis betulina), Red-belted Conk (Fomitopsis pinicola), Reishi / Lacquer Conk (Ganoderma lingzhi) , Agarikon/Quinine Conk (Laricifomes officinalis), False Tinder Polypore (Fomes fomentarius), Chaga Clinker Polypore (Inonotus obliquus), Birch Mazegill (Trametes betulina), Turkey Tail (Trametes versicolor), Cordyceps - Scarlet Caterpillarclub (Cordyceps militaris), Lion’s Main(Hericium erinaceus) and Morels (Morchella). AREV plans to assess each for its characteristics and functional value so the Company can focus on mass production of two or three mushrooms as an efficient and efficacious source of plant-based protein.

According to the Good Food Institute, a respected non-profit in this field, the plant-based sector compound annual growth rate (CAGR) will be 27% over the next 5 years. The Good Food Institute further claims that as of today, approximately 57% of North American households have purchased plant-based foods, with roughly 78% of such households engaging in repeat orders.

With the world focused on environmental, social, and governance (ESG) metrics, along with enhanced nutrition and health, UBS forecasts the plant-based foods market space to dramatically increase from about USD $5 billion to $85 billion by 2030. Bloomberg also projects that plant-based meat could make up a quarter of the USD $1.8 trillion meat market by 2040.

Mr. Michael Withrow, CEO of AREV, stated, “Our Cambodia operations are doing great work. We can now move forward with confidence that the cultivation conditions are prime for producing plant-based proteins that can be marketed globally and integrated into our SUS-TAINN™ Branded RUTF in development.”

For further information, contact Mike Withrow, mike@AREVBrands.com 778-929-6536. For more information visit arevlifesciences.com

On behalf of the Board,

Mike Withrow
CEO & Director

About AREV NanoTec Inc.  
AREV (AREV) is a fully integrated, early-stage life science discovery enterprise dedicated to delivering solutions to public healthcare metrics through innovations and successful collaborations in the life science industry. Our strategy is dedicated to generating revenue by way of novel therapeutic approaches to human nutrition and malnutrition, pandemic diseases, and neglected chronic co-morbidities. We are invested in commercial innovations in phytomedicinal discoveries of small molecule antivirals and have a significant footprint in human nutrition including the development of a Ready-to-Use Therapeutic Food (RUTF) for Severe Acute Malnutrition (SAM) and an Enteral Formula targeting the long-term effects of COVID-19. AREV is dedicated to designing and delivering innovation in nutritional therapeutics and rational drug design, driven by molecular epidemiology. AREV’s business model is driven by leveraging its core competency of extraction to produce ingredients and compounds for its pipeline of products.

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

FORWARD LOOKING INFORMATION

Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in policies of the CSE) accepts responsibility for the adequacy or accuracy of this release. This news release may include forward-looking statements that are subject to risks and uncertainties. All statements within, other than statements of historical fact, are to be considered forward looking. Although the Company believes the expectations expressed in such forward looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those in forward-looking statements. Factors that could cause actual results to differ materially from those in forward-looking statements include market prices, exploitation and exploration successes, and continued availability of capital and financing, and general economic, market or business conditions. There can be no assurances that such statements will prove accurate and, therefore, readers are advised to rely on their own evaluation of such uncertainties. We do not assume any obligation to update any forward-looking statements except as required under the applicable laws. This press release contains forward-looking statements. The use of any of the words "anticipate", "continue", "estimate", "expect", "may", "will", "project", "should", "believe" and similar expressions are intended to identify forward-looking statements.  Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this press release. Actual results could differ materially from those currently anticipated due to a number of factors and risks various risk factors discussed in the Company’s Management’s Discussion and Analysis under the Company’s profile on www.sedar.com.